Pharsight

Almirall patents expiration

1. Aczone patents expiration

ACZONE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6060085 ALMIRALL Compositions and methods for topical application of therapeutic agents
Sep, 2016

(7 years ago)

US5863560 ALMIRALL Compositions and methods for topical application of therapeutic agents
Sep, 2016

(7 years ago)

US6620435 ALMIRALL Compositions for topical application of therapeutic agents
Sep, 2016

(7 years ago)

US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(9 years from now)

US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Nov, 2033

(9 years from now)

US11273132 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Feb 24, 2019
New Patient Population(NPP) Sep 10, 2022

Drugs and Companies using DAPSONE ingredient

Market Authorisation Date: 24 February, 2016

Treatment: Treatment of acne; Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

How can I launch a generic of ACZONE before it's drug patent expiration?
More Information on Dosage

ACZONE family patents

Family Patents

2. Altabax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39128 ALMIRALL Pleuromutilin derivatives as antimicrobials
Apr, 2021

(3 years ago)

USRE43390 ALMIRALL Pleuromutilin derivatives as antimicrobials
Apr, 2021

(3 years ago)

US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2012

Drugs and Companies using RETAPAMULIN ingredient

NCE-1 date: 13 April, 2011

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

ALTABAX family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Klisyri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(1 year, 6 months from now)

US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(1 year, 6 months from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(1 year, 7 months from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(4 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(3 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(13 years from now)

US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 14 December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

KLISYRI family patents

Family Patents

4. Seysara patents expiration

Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8318706 ALMIRALL Substituted tetracycline compounds
May, 2031

(6 years from now)

US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9481639 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders
Aug, 2028

(4 years from now)

US8513223 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 01, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: 01 October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg...

Dosage: TABLET;ORAL

More Information on Dosage

SEYSARA family patents

Family Patents

5. Solage patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5194247 ALMIRALL Synergistic skin depigmentation composition
Dec, 2013

(10 years ago)

US6353029 ALMIRALL Storage stable tretinoin and 4-hydroxyanisole containing topical composition
Aug, 2020

(3 years ago)

Drugs and Companies using MEQUINOL; TRETINOIN ingredient

Market Authorisation Date: 10 December, 1999

Treatment: Treatment of hyperpigmentary disorders

Dosage: SOLUTION;TOPICAL

More Information on Dosage

SOLAGE family patents

Family Patents

6. Veltin patents expiration

VELTIN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5690923 ALMIRALL Stable topical retinoid compositions
Nov, 2014

(9 years ago)

US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(1 year, 2 months from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE; TRETINOIN ingredient

Market Authorisation Date: 16 July, 2010

Treatment: Treatment of atopic dermatitis

Dosage: GEL;TOPICAL

More Information on Dosage

VELTIN family patents

Family Patents

7. Verdeso patents expiration

VERDESO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6730288 ALMIRALL Mousse composition
Sep, 2019

(4 years ago)

US7029659 ALMIRALL Mousse composition
Sep, 2019

(4 years ago)

US8962000 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(1 year, 2 months from now)

US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(1 year, 2 months from now)

US8460641 ALMIRALL Microemulsion process and composition
Aug, 2027

(3 years from now)

Drugs and Companies using DESONIDE ingredient

Market Authorisation Date: 19 September, 2006

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

VERDESO family patents

Family Patents

8. Xolegel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735393 ALMIRALL Anhydrous topical skin preparations
Dec, 2018

(5 years ago)

US7179475 ALMIRALL Anhydrous topical skin preparations
Dec, 2018

(5 years ago)

US8232276 ALMIRALL Anhydrous topical skin preparations
Nov, 2020

(3 years ago)

Drugs and Companies using KETOCONAZOLE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: Treatment of seborrhea dermatitis in humans

Dosage: GEL;TOPICAL

More Information on Dosage

XOLEGEL family patents

Family Patents